AstraZeneca, Kyowa Hakko Kirin deal

AstraZeneca granted Kyowa’s ProStrakan Group plc subsidiary exclusive rights to develop and commercialize Moventig

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE